IN RESPONSE:
In our study, use of any kind of drug affecting the pituitary function was an exclusion criterion. None of the retired amateur boxers had a history of using any performance-enhancing drug, such as anabolic steroids or growth hormone, during their career. Although the use of doping agents, growth hormone in particular, is well known among professional athletes in Western countries (1), growth hormone vials were not available in Turkey, especially during the years of the retired boxers' active careers. Moreover, to avoid the use of doping agents, national and international amateur boxing federations have very strict regulations.
Although not enough data are available on the effects of longterm use of growth hormone on pituitary function and volume in athletes, one might expect the suppression of the growth hormone axis and decreased pituitary volume as suggested. However, after the cessation of growth hormone or anabolic steroids, the suppression of the relevant axis recovers over several months or rarely several years. The mean time since retirement was 16 years (range, 8 to 28 years) in our retired boxer group, enough time to recover from all possible drug-related changes.
In addition, there were significant negative correlations between the length of boxing career and growth hormone reserve. If retired boxers had used growth hormone, both growth hormone-deficient and growth hormone-normal boxers would be expected to have decreased pituitary volume. However, growth hormone-deficient retired boxers had significantly decreased pituitary volume when compared with growth hormone-normal retired boxers.
In a meta-analysis including the patients with head traumainduced hypopituitarism due to various causes other than sports, growth hormone deficiency is the most common problem, and the rate of isolated hormone deficiencies is higher than the rate of multiple hormone deficiencies (2) . Therefore, presence of the isolated hormone deficiencies, growth hormone deficiency in particular, was not surprising in our group of boxers. The anatomical localization of the growth hormone-secreting cells in the pituitary gland, which are located at the outer border and lateral wings, could be 1 possible explanation for the vulnerability of these cells to trauma. Moreover, in a very recent study, apolipoprotein E3/E3 genotype was shown to decrease the risk for trauma-induced hypopituitarism in boxers and kickboxers, suggesting a genetic susceptibility (3) .
In conclusion, evidence shows that hypopituitarism in retired boxers is due to sports-related, long-term head trauma and could not be explained by possible use of doping agents. In addition, assuming a misuse of growth hormone by the boxers in our study (which is not the case) leads to overlooking the potential hazards of boxing on pituitary function. However, it would be interesting to investigate the pituitary consequences of long-term use of doping agents in professional athletes who had a clear history of using them. What exactly does "prehypertension" mean, and why is its use so persistent? Prehypertension means blood pressure within or slightly above the normal range-in other words, it is a way of categorizing what is a continuous variable (blood pressure). I speculate that this term has come into vogue because "prehypertension" sounds like an illness; it sounds like a necessary precursor to hypertension, part of a slippery slope. In this respect, it resembles such terms as "premalignant." But it is not really the same as "premalignant," because even hypertension is simply a way of categorizing a continuous variable. There is no magic threshold of blood pressure that is free of risk for vascular disease. We have known this for decades. Higher blood pressure means higher incidence of vascular disease, and "higher" is a relative term. Persons whose usual blood pressure is 115/70 mm Hg are at lower risk for vascular disease than those whose usual blood pressure is 120/75 mm Hg, and so on. We also know that blood pressure tends to increase with age. Those with higher blood pressures when young are likely to end up with higher blood pressures when older. So what are we being told here? People with higher-than-average blood pressures are at higher-than-average risk for vascular disease-something we have known since the first Framingham study was published decades ago.
The use of this half-baked term persists because it sounds like an illness and thus is a gift to marketers of hypotensive drugs. The TROPHY (Trial for Preventing Hypertension) study drew the absurd conclusion that we could prevent hypertension (a condition effectively defined as eligibility for drug treatment) by starting drug treatment. Another reason is that, in the United States, there is great attachment to using categorical variables to define eligibility for hypotensive treatment, whereas in much of the rest of the world (led by New Zealand), eligibility for treatment is determined by calculating predicted incidence of cardiovascular disease as a continuous variable. Is this just failure of imagination in the United States? Ironically, New Zealand guidelines use the U.S. Framingham equation to predict risk, whereas the United States guidelines rarely use it. The answer may be more prosaic. Most primary care physicians in the United States do not have electronic medical records. In New Zealand, Australia, the United Kingdom, the Netherlands, and Scandinavia, it is almost unheard of for a primary care physician to lack electronic medical records, and electronic medical records make Framingham risk calculations simple. So while the rest of the world moves toward an understanding of cardiovascular disease risk that is based on predicted incidence of illness, the United States simply attempts to expand the categorical variable that encompasses those defined as eligible for treatment. ported by Grossman (1). These patients received treatment at a time when supplies of the antibiotic were limited and the purity could not be guaranteed. Despite these shortcomings, the initial responses to treatment were positive even if the final outcome was not. Although their stories are not as gratifying as that of a young woman cured of a deadly infection, it is important to properly recognize the first patients treated with penicillin for the contributions they made.
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Does Furosemide Have a Role in the Management of Hypercalcemia?
TO THE EDITOR: LeGrand and colleagues (1) concluded, on the basis of their recent review of the literature, that furosemide has no role in the modern management of hypercalcemia. We take issue with this contention and note the fundamental limitations of their analysis.
Bisphosphonates attenuate bone calcium mobilization and address a major-but not the sole-clinical contributor to hypercalcemia. Hypercalcemia may also result from increased gastrointestinal calcium uptake. Decreased renal excretion alone does not cause hypercalcemia but does aggravate hypercalcemia from other causes. Volume contraction and dehydration due to natriuresis and nephrogenic diabetes insipidus, respectively, also amplify hypercalcemia of all causes. The calciuretic effect of furosemide and its enhancement by volume expansion, however, are well established: Natriuresis promotes calciuresis.
In our opinion, the authors' analysis neither demonstrated nor excluded therapeutic benefits of furosemide. That the therapy is "unproven" by systematic reviews does not invalidate a wealth of experimental and clinical data suggesting benefit (2-5). Indeed, the overwhelming majority of patients with hypercalcemia detailed by the authors improved or normalized in response to calciuretic therapy with furosemide (1). Our own clinical experience is similar, although the effectiveness of furosemide clearly depends on adequate attention to volume status and fluid balance before and during therapy.
Bisphosphonates are not without substantial adverse sequelae or expense, so alternative therapeutic options are needed for patients that cannot tolerate or afford them. We acknowledge the important role of bisphosphonates in the treatment of hypercalcemia, but regard the monolithic contention that calciuretic therapy has no utility in the treatment of hypercalcemia as both misplaced and unsupported by the data. The additive effects of bisphosphonates and calciuretic therapy are well-suited for combination therapy, and we contend that furosemide remains an important tool in the wellprepared physician's therapeutic arsenal. The authors' anecdotal accounts of widespread nonadherence to recommended guidelines for concomitant saline administration suggest a need to educate clinicians in the proper use of furosemide therapy, not a need to dismiss this intervention.
The article by LeGrand and colleagues reflects a recent trend in the literature that discounts fundamental physiologic principles and favors pure statistical considerations in determining "best" evidence. This article's selection for associated CME activities in this journal is also unfortunate, because this tacitly validates conclusions that are not fully supported by the data. The authors have, however, raised an important issue that can best be addressed by a well-designed randomized, controlled trial comparing bisphosphonate therapy alone and in combination with calciuretic therapy in carefully matched patients with hypercalcemia. IN RESPONSE: Dr. Robey and colleagues question our conclusion that furosemide has no role other than management of fluid overload; however, we are not alone in this conclusion (1-3; www.uptodateonline.com). The fact that furosemide produces calciuria is not in question. The question is whether this translates into a practical therapy for malignant hypercalcemia. What we found was not a "wealth," but a paucity of evidence for the value of furosemide and no evidence to support the currently recommended doses. The other key element in the case reports was the intensity of monitoring to ensure adequate rehydration and replacement of urine loss, which is certainly not standard today and would substantially increase the cost of therapy. Only one third (not an "overwhelming majority") of patients achieved normalized calcium levels, with duration of response not reported. The goal of therapy should be a normal-not just improved-calcium level.
R. Brooks Robey, MD
Dr. Robey and colleagues overstate the toxicity of the single dose of bisphosphonates required for hypercalcemia. Toxicity is minimal-typically fever-and in the acute care setting, it is administered on an inpatient basis, so access to the medications is not an issue. The toxicity and cost issues noted are a concern for long-term rather than short-term use. Delaying institution of bisphosphonates prolongs length of stay and might outweigh any cost advantage, although no comparison studies have been published. Withholding bisphosphonates may result in rapid relapse once hydration is stopped, particularly in a palliative setting in which disease-specific therapy may not exist.
Although I agree that one could conduct a randomized trial of bisphosphonates with and without furosemide, there are too many unanswered questions to ethically proceed. What dose of furosemide would one use? What evidence would determine this dose? Would you conduct phase I trials to determine the appropriate dose first? How would one determine adequate hydration in the furosemide group? There are many more critical things to research and newer therapies under evaluation as we continue to understand the cytokines involved in malignant hypercalcemia. Teach fluids and bisphosphonates; they are easy to learn and have less potential for harm from over-or underhydration. catheter, orthopedic hardware) and immunosuppression, such as that caused by cancer (1) .
Tsukamurella species require more than 2 weeks to grow in culture media and are easily missed if cultures are not held for a longer period or if AFB cultures are not obtained.
Reports of nonpulmonary infection with Tsukamurella species indicate the need for long-term antibiotic therapy (1) (2) (3) (4) . Tsukamurella pulmonis is known to be resistant to conventional grampositive regimens, with the exception of vancomycin and rifampin. A review of published case reports supports an initial regimen of a ␤-lactam plus an aminoglycoside or a macrolide plus a quinolone (1) (2) (3) (4) .
Conclusion: Tsukamurella pulmonis is a cause of communityacquired pneumonia. Cultures must be kept for at least 2 weeks to identify this organism; thus, it may be more prevalent in the community than previously recognized. Top. Chest radiographs on hospital days 1 (left) and 10 (right). Bottom. Computed tomography scans of the chest on hospital day 2 (left) and at 8 weeks after hospital discharge (right).
